Addition of Six-His-Tagged Peptide to the C Terminus of Adeno-Associated Virus VP3 Does Not Affect Viral Tropism or Production
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Production of large quantities of recombinant adeno-associated virus (AAV) is difficult and not cost-effective. To overcome this problem, we have explored the feasibility of creating a recombinant AAV encoding a 6×His tag on the VP3 capsid protein. We generated a plasmid vector containing a six-His (6×His)-tagged AAV VP3. A second plasmid vector was generated that contained the full-length AAV capsid capable of producing VP1 and VP2, but not VP3 due to a mutation at position 2809 that encodes the start codon for VP3. These plasmids, necessary for production of AAV, were transfected into 293 cells to generate a 6×His-tagged VP3mutant recombinant AAV. The 6×His-tagged VP3 did not affect the formation of AAV virus, and the physical properties of the 6×His-modified AAV were equivalent to those of wild-type particles. The 6×His-tagged AAV did not affect the production titer of recombinant AAV and could be used to purify the recombinant AAV using an Ni-nitrilotriacetic acid column. Addition of the 6×His tag did not alter the viral tropism compared to wild-type AAV. These observations demonstrate the feasibility of producing high-titer AAV containing a 6×His-tagged AAV VP3 capsid protein and to utilize the 6×His-tagged VP3 capsid to achieve high-affinity purification of this recombinant AAV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Electron cryo‐microscopy and image reconstruction of adeno‐associated virus type 2 empty capsids
Kronenberg, S., Kleinschmidt, J. A., & Böttcher, B. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve234 · Cited by 161 · cited 1×
“The C-terminal region sequences that are common to all three capsid proteins promote folding of the C-terminal region of the polypeptide into a -barrel structure, which is present in several viruses, including parvovirus B19 and porcine parvovirus (1, 5, 7, 18, 19, 26).”
BackgroundInsertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus
Rabinowitz, J. E., Xiao, W., & Samulski, R. J. (1999) · Virology · doi:10.1006/viro.1999.0045 · Cited by 136 · cited 1×
“A recent insertional mutation study of the AAV capsid proteins revealed that mutations in the capsid gene could affect AAV capsid assembly and infection (22).”
BackgroundRuffing, M., Zentgraf, H., & Kleinschmidt, J. A. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.6922-6930.1992 · Cited by 109 · cited 1×
“The relative abundance of VP3 within the capsid is considerably higher (90%), than that of VP1 (5%) and VP2 (5%) (24, 29, 32).”
BackgroundAssembly of adeno-associated virus type 2 capsids in vitro.
Steinbach, S., Kleinschmidt, J. A., Wistuba, A., & Bock, T. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-6-1453 · Cited by 52 · cited 1×
“The relative abundance of VP3 within the capsid is considerably higher (90%), than that of VP1 (5%) and VP2 (5%) (24, 29, 32).”
Background
Cited by
Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
Warrington, K. H., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S., & Muzyczka, N. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6595-6609.2004 · Cited by 205
Lochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201
AAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191
“In a different study, Zhang et al (2002) described a chimeric AAV, composed of wt AAV VP1 and 2 proteins, and a C-terminal 6-His-tagged VP3, which yielded infectious and wt-like virus that can be readily purified by using a Ninitrilotriacetic acid column [Zhang, HG et al., 2002].”
MethodTailoring the AAV vector capsid for gene therapy
Vandenberghe, L. H., Wilson, J. M., & Gao, G. (2009) · Gene Therapy · doi:10.1038/gt.2008.170 · Cited by 155
Metadata
- Authors
- Zhang, H.-G., Xie, J., Dmitriev, I., Kashentseva, E., Curiel, D. T., Hsu, H.-C., & Mountz, J. D.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2002-12
- Volume
- 76
- Issue
- 23
- Pages
- 12023-12031
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2107753368
- Cited by
- 39
- References
- 6
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addition of Six-His-Tagged Peptide to the C Terminus of Adeno-Associated Virus VP3 Does Not Affect Viral Tropism or Production. https://app.cochat.ai/papers/10.1128/jvi.76.23.12023-12031.2002
- The paper
- Zhang, H.-G., Xie, J., Dmitriev, I., Kashentseva, E., Curiel, D. T., Hsu, H.-C., & Mountz, J. D. (2002). Addition of Six-His-Tagged Peptide to the C Terminus of Adeno-Associated Virus VP3 Does Not Affect Viral Tropism or Production. Journal of Virology. https://doi.org/10.1128/jvi.76.23.12023-12031.2002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.